Mass balance, metabolism, and pharmacokinetics of [14C]amdizalisib, a clinical-stage novel oral selective PI3Kδ inhibitor for the treatment of non-hodgkin’s lymphoma, in healthy Chinese volunteers

Authors

Jingying Jia (ORCID: https://orcid.org/0000-0002-2492-3219)
Chengyin Yu (ORCID: https://orcid.org/0000-0001-8665-0140)
Gangyi Liu
Qian Chen (ORCID: https://orcid.org/0000-0001-9834-6912)
Jian Wang (ORCID: https://orcid.org/0000-0002-7848-803X)
Wei Wang (ORCID: https://orcid.org/0000-0002-5386-9530)
Yang Sai (ORCID: https://orcid.org/0000-0002-5742-116X)
Yanmei Liu
Chan Sun (ORCID: https://orcid.org/0009-0004-5211-9393)
Chunyang Zhao (ORCID: https://orcid.org/0009-0004-4351-9336)
Weiguo Su (ORCID: https://orcid.org/0000-0002-6482-3300)
Lijun Zhang (ORCID: https://orcid.org/0000-0003-4974-2745)

Institutions

Chinese Academy of Sciences (CN)
Fudan University (CN)
Shanghai Institute of Materia Medica (CN)
Shanghai Xuhui Central Hospital (CN)
Shanghai Clinical Research Center (CN)

Publication Details

Journal: Frontiers in Pharmacology
Published: 2024-11-15
DOI: https://doi.org/10.3389/fphar.2024.1478234
Primary Topic: Chronic Lymphocytic Leukemia Research
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Clinical Trial Center, China Medical University Hospital
Fudan University
Shanghai Xuhui District Central Hospital

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Mass balance, metabolism, and pharmacokinetics of [14C]amdizalisib, a clinical-stage novel oral selective PI3Kδ inhibitor for the treatment of non-hodgkin’s lymphoma, in healthy Chinese volunteers

Jingying Jia, Chengyin Yu, Gangyi Liu, Qian Chen et al.

Nov 15, 2024

1 links

Frontiers in Pharmacology

Chronic Lymphocytic Leukemia Research

article

Mass balance, metabolism, and pharmacokinetics of [14C]amdizalisib, a clinical-stage novel oral selective PI3Kδ inhibitor for the treatment of non-hodgkin’s lymphoma, in healthy Chinese volunteers

Jingying Jia, Chengyin Yu, Gangyi Liu, Qian Chen, Jian Wang, Wei Wang, Yang Sai, Yanmei Liu, Chan Sun, Chunyang Zhao, Weiguo Su, Lijun Zhang

November 15, 2024article en

Abstract

No abstract available for this paper.

Frontiers in PharmacologyVol. 15

Chinese Academy of Sciences (CN), Fudan University (CN), Shanghai Institute of Materia Medica (CN), Shanghai Xuhui Central Hospital (CN), Shanghai Clinical Research Center (CN)

Clinical Trial Center, China Medical University Hospital, Fudan University, Shanghai Xuhui District Central Hospital

Good health and well-being

Openalex Percentile: Top 63%

Chronic Lymphocytic Leukemia Research

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Mass balance, metabolism, and pharmacokinetics of [14C]amdizalisib, a clinical-stage novel oral selective PI3Kδ inhibitor for the treatment of non-hodgkin’s lymphoma, in healthy Chinese volunteers — Jingying Jia, Chengyin Yu, et al. · Frontiers in Pharmacology (2024) | TGRS Research Map | TGRS